Compile Data Set for Download or QSAR
maximum 50k data
Found 945 with Last Name = 'farnaby' and Initial = 'w'
TargetLysophosphatidic acid receptor 1(Homo sapiens (Human))
Takeda Pharmaceutical

US Patent
LigandPNGBDBM251697(US10100018, Example 33 | US9464060, 33)
Affinity DataIC50:  0.300nMT: 2°CAssay Description:Engagement of the LPA1 receptor by its ligand, oleoyl-L-α-lysophosphatidic acid (LPA), leads to the release of intracellular stores of calcium into ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetLysophosphatidic acid receptor 1(Homo sapiens (Human))
Takeda Pharmaceutical

US Patent
LigandPNGBDBM251697(US10100018, Example 33 | US9464060, 33)
Affinity DataIC50:  0.300nMT: 2°CAssay Description:Engagement of the LPA1 receptor by its ligand, oleoyl-L-α-lysophosphatidic acid (LPA), leads to the release of intracellular stores of calcium i...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetLysophosphatidic acid receptor 1(Homo sapiens (Human))
Takeda Pharmaceutical

US Patent
LigandPNGBDBM251681(US10100018, Example 17 | US9464060, 17)
Affinity DataIC50:  0.400nMT: 2°CAssay Description:Engagement of the LPA1 receptor by its ligand, oleoyl-L-α-lysophosphatidic acid (LPA), leads to the release of intracellular stores of calcium into ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetLysophosphatidic acid receptor 1(Homo sapiens (Human))
Takeda Pharmaceutical

US Patent
LigandPNGBDBM251681(US10100018, Example 17 | US9464060, 17)
Affinity DataIC50:  0.400nMT: 2°CAssay Description:Engagement of the LPA1 receptor by its ligand, oleoyl-L-α-lysophosphatidic acid (LPA), leads to the release of intracellular stores of calcium i...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetLysophosphatidic acid receptor 1(Homo sapiens (Human))
Takeda Pharmaceutical

US Patent
LigandPNGBDBM251696(US10100018, Example 32 | US9464060, 32)
Affinity DataIC50:  0.400nMT: 2°CAssay Description:Engagement of the LPA1 receptor by its ligand, oleoyl-L-α-lysophosphatidic acid (LPA), leads to the release of intracellular stores of calcium i...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetLysophosphatidic acid receptor 1(Homo sapiens (Human))
Takeda Pharmaceutical

US Patent
LigandPNGBDBM251697(US10100018, Example 33 | US9464060, 33)
Affinity DataIC50:  0.400nMT: 2°CAssay Description:Engagement of the LPA1 receptor by its ligand, oleoyl-L-α-lysophosphatidic acid (LPA), leads to the release of intracellular stores of calcium i...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetLysophosphatidic acid receptor 5(Homo sapiens (Human))
Takeda Pharmaceutical

US Patent
LigandPNGBDBM251697(US10100018, Example 33 | US9464060, 33)
Affinity DataIC50:  0.400nMT: 2°CAssay Description:Engagement of the LPA5 receptor by its ligand, oleoyl-L-α-lysophosphatidic acid (LPA), leads to the release of intracellular stores of calcium into ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetLysophosphatidic acid receptor 5(Homo sapiens (Human))
Takeda Pharmaceutical

US Patent
LigandPNGBDBM251696(US10100018, Example 32 | US9464060, 32)
Affinity DataIC50:  0.400nMT: 2°CAssay Description:Engagement of the LPA5 receptor by its ligand, oleoyl-L-α-lysophosphatidic acid (LPA), leads to the release of intracellular stores of calcium into ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetCholesterol 24-hydroxylase(Homo sapiens (Human))TBA
LigandPNGBDBM50609199(CHEMBL5279173)
Affinity DataIC50:  1nMAssay Description:Inhibition of full length N-terminal his6-tagged human CH24H (28 to 494 residues) expressed in Escherichia coli DH5alpha using [14C] cholesterol as s...More data for this Ligand-Target Pair
Ligand Info
In DepthDetails PubMed
TargetLysophosphatidic acid receptor 1(Homo sapiens (Human))
Takeda Pharmaceutical

US Patent
LigandPNGBDBM251682(US10100018, Example 18 | US9464060, 18)
Affinity DataIC50:  1nMT: 2°CAssay Description:Engagement of the LPA1 receptor by its ligand, oleoyl-L-α-lysophosphatidic acid (LPA), leads to the release of intracellular stores of calcium i...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetLysophosphatidic acid receptor 1(Homo sapiens (Human))
Takeda Pharmaceutical

US Patent
LigandPNGBDBM251680(US10100018, Example 16 | US9464060, 16)
Affinity DataIC50:  1nMT: 2°CAssay Description:Engagement of the LPA1 receptor by its ligand, oleoyl-L-α-lysophosphatidic acid (LPA), leads to the release of intracellular stores of calcium i...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetLysophosphatidic acid receptor 5(Homo sapiens (Human))
Takeda Pharmaceutical

US Patent
LigandPNGBDBM251681(US10100018, Example 17 | US9464060, 17)
Affinity DataIC50:  1nMT: 2°CAssay Description:Engagement of the LPA5 receptor by its ligand, oleoyl-L-α-lysophosphatidic acid (LPA), leads to the release of intracellular stores of calcium into ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetLysophosphatidic acid receptor 1(Homo sapiens (Human))
Takeda Pharmaceutical

US Patent
LigandPNGBDBM251682(US10100018, Example 18 | US9464060, 18)
Affinity DataIC50:  1nMT: 2°CAssay Description:Engagement of the LPA1 receptor by its ligand, oleoyl-L-α-lysophosphatidic acid (LPA), leads to the release of intracellular stores of calcium into ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetLysophosphatidic acid receptor 5(Homo sapiens (Human))
Takeda Pharmaceutical

US Patent
LigandPNGBDBM251680(US10100018, Example 16 | US9464060, 16)
Affinity DataIC50:  1nMT: 2°CAssay Description:Engagement of the LPA5 receptor by its ligand, oleoyl-L-α-lysophosphatidic acid (LPA), leads to the release of intracellular stores of calcium into ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetLysophosphatidic acid receptor 1(Homo sapiens (Human))
Takeda Pharmaceutical

US Patent
LigandPNGBDBM251681(US10100018, Example 17 | US9464060, 17)
Affinity DataIC50:  1nMT: 2°CAssay Description:Engagement of the LPA1 receptor by its ligand, oleoyl-L-α-lysophosphatidic acid (LPA), leads to the release of intracellular stores of calcium i...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetLysophosphatidic acid receptor 1(Homo sapiens (Human))
Takeda Pharmaceutical

US Patent
LigandPNGBDBM251678(US10100018, Example 14 | US9464060, 14)
Affinity DataIC50:  2nMT: 2°CAssay Description:Engagement of the LPA1 receptor by its ligand, oleoyl-L-α-lysophosphatidic acid (LPA), leads to the release of intracellular stores of calcium i...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetLysophosphatidic acid receptor 5(Homo sapiens (Human))
Takeda Pharmaceutical

US Patent
LigandPNGBDBM251678(US10100018, Example 14 | US9464060, 14)
Affinity DataIC50:  2nMT: 2°CAssay Description:Engagement of the LPA5 receptor by its ligand, oleoyl-L-α-lysophosphatidic acid (LPA), leads to the release of intracellular stores of calcium into ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetLysophosphatidic acid receptor 1(Homo sapiens (Human))
Takeda Pharmaceutical

US Patent
LigandPNGBDBM251678(US10100018, Example 14 | US9464060, 14)
Affinity DataIC50:  2nMT: 2°CAssay Description:Engagement of the LPA1 receptor by its ligand, oleoyl-L-α-lysophosphatidic acid (LPA), leads to the release of intracellular stores of calcium i...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetLysophosphatidic acid receptor 1(Homo sapiens (Human))
Takeda Pharmaceutical

US Patent
LigandPNGBDBM251696(US10100018, Example 32 | US9464060, 32)
Affinity DataIC50:  2nMT: 2°CAssay Description:Engagement of the LPA1 receptor by its ligand, oleoyl-L-α-lysophosphatidic acid (LPA), leads to the release of intracellular stores of calcium i...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetLysophosphatidic acid receptor 5(Homo sapiens (Human))
Takeda Pharmaceutical

US Patent
LigandPNGBDBM251682(US10100018, Example 18 | US9464060, 18)
Affinity DataIC50:  2nMT: 2°CAssay Description:Engagement of the LPA5 receptor by its ligand, oleoyl-L-α-lysophosphatidic acid (LPA), leads to the release of intracellular stores of calcium into ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetLysophosphatidic acid receptor 1(Homo sapiens (Human))
Takeda Pharmaceutical

US Patent
LigandPNGBDBM251682(US10100018, Example 18 | US9464060, 18)
Affinity DataIC50:  2nMT: 2°CAssay Description:Engagement of the LPA1 receptor by its ligand, oleoyl-L-α-lysophosphatidic acid (LPA), leads to the release of intracellular stores of calcium i...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetLysophosphatidic acid receptor 1(Homo sapiens (Human))
Takeda Pharmaceutical

US Patent
LigandPNGBDBM251678(US10100018, Example 14 | US9464060, 14)
Affinity DataIC50:  2nMT: 2°CAssay Description:Engagement of the LPA1 receptor by its ligand, oleoyl-L-α-lysophosphatidic acid (LPA), leads to the release of intracellular stores of calcium into ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetLysophosphatidic acid receptor 1(Homo sapiens (Human))
Takeda Pharmaceutical

US Patent
LigandPNGBDBM251696(US10100018, Example 32 | US9464060, 32)
Affinity DataIC50:  2nMT: 2°CAssay Description:Engagement of the LPA1 receptor by its ligand, oleoyl-L-α-lysophosphatidic acid (LPA), leads to the release of intracellular stores of calcium into ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetCholesterol 24-hydroxylase(Homo sapiens (Human))TBA
LigandPNGBDBM50609193(CHEMBL5288661)
Affinity DataIC50:  2.40nMAssay Description:Inhibition of full length N-terminal his6-tagged human CH24H (28 to 494 residues) expressed in Escherichia coli DH5alpha using [14C] cholesterol as s...More data for this Ligand-Target Pair
Ligand Info
In DepthDetails PubMed
TargetCholesterol 24-hydroxylase(Homo sapiens (Human))TBA
LigandPNGBDBM50609182(CHEMBL5276973)
Affinity DataIC50:  2.70nMAssay Description:Inhibition of full length N-terminal his6-tagged human CH24H (28 to 494 residues) expressed in Escherichia coli DH5alpha using [14C] cholesterol as s...More data for this Ligand-Target Pair
Ligand InfoPDB
TargetLysophosphatidic acid receptor 1(Homo sapiens (Human))
Takeda Pharmaceutical

US Patent
LigandPNGBDBM251677(US10100018, Example 13 | US9464060, 13)
Affinity DataIC50:  3nMT: 2°CAssay Description:Engagement of the LPA1 receptor by its ligand, oleoyl-L-α-lysophosphatidic acid (LPA), leads to the release of intracellular stores of calcium i...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetLysophosphatidic acid receptor 5(Homo sapiens (Human))
Takeda Pharmaceutical

US Patent
LigandPNGBDBM251677(US10100018, Example 13 | US9464060, 13)
Affinity DataIC50:  3nMT: 2°CAssay Description:Engagement of the LPA5 receptor by its ligand, oleoyl-L-α-lysophosphatidic acid (LPA), leads to the release of intracellular stores of calcium into ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetD-amino-acid oxidase(Homo sapiens (Human))
Takeda Pharmaceutical

US Patent
LigandPNGBDBM210775(US10463663, Example 4 | US11129828, Example 4 | US...)
Affinity DataIC50:  3.70nMpH: 7.4 T: 2°CAssay Description:Human DAAO enzyme was supplied by the Takeda Pharmaceutical Company (Osaka) and each batch was tested and used at concentrations giving comparable le...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetD-amino-acid oxidase(Homo sapiens (Human))
Takeda Pharmaceutical

US Patent
LigandPNGBDBM210775(US10463663, Example 4 | US11129828, Example 4 | US...)
Affinity DataIC50:  3.70nMAssay Description:The functional activity of compounds inhibiting the DAAO enzyme was determined by utilizing the co-product of the catalysis of D-Serine, H2O2 which c...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetD-amino-acid oxidase(Homo sapiens (Human))
Takeda Pharmaceutical

US Patent
LigandPNGBDBM210775(US10463663, Example 4 | US11129828, Example 4 | US...)
Affinity DataIC50:  3.70nMAssay Description:Human DAAO enzyme was supplied by the Takeda Pharmaceutical Company (Osaka) and each batch was tested and used at concentrations giving comparable le...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetD-amino-acid oxidase(Homo sapiens (Human))
Takeda Pharmaceutical

US Patent
LigandPNGBDBM210775(US10463663, Example 4 | US11129828, Example 4 | US...)
Affinity DataIC50:  3.70nMAssay Description:Human DAAO enzyme was supplied by the Takeda Pharmaceutical Company (Osaka) and each batch was tested and used at concentrations giving comparable le...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetLysophosphatidic acid receptor 1(Homo sapiens (Human))
Takeda Pharmaceutical

US Patent
LigandPNGBDBM251695(US10100018, Example 31 | US9464060, 31)
Affinity DataIC50:  4nMT: 2°CAssay Description:Engagement of the LPA1 receptor by its ligand, oleoyl-L-α-lysophosphatidic acid (LPA), leads to the release of intracellular stores of calcium i...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetLysophosphatidic acid receptor 1(Homo sapiens (Human))
Takeda Pharmaceutical

US Patent
LigandPNGBDBM251695(US10100018, Example 31 | US9464060, 31)
Affinity DataIC50:  4nMT: 2°CAssay Description:Engagement of the LPA1 receptor by its ligand, oleoyl-L-α-lysophosphatidic acid (LPA), leads to the release of intracellular stores of calcium into ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetLysophosphatidic acid receptor 1(Homo sapiens (Human))
Takeda Pharmaceutical

US Patent
LigandPNGBDBM251677(US10100018, Example 13 | US9464060, 13)
Affinity DataIC50:  4nMT: 2°CAssay Description:Engagement of the LPA1 receptor by its ligand, oleoyl-L-α-lysophosphatidic acid (LPA), leads to the release of intracellular stores of calcium into ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetLysophosphatidic acid receptor 5(Homo sapiens (Human))
Takeda Pharmaceutical

US Patent
LigandPNGBDBM251729(US10100018, Example 65 | US9464060, 65)
Affinity DataIC50:  4nMT: 2°CAssay Description:Engagement of the LPA5 receptor by its ligand, oleoyl-L-α-lysophosphatidic acid (LPA), leads to the release of intracellular stores of calcium into ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetLysophosphatidic acid receptor 1(Homo sapiens (Human))
Takeda Pharmaceutical

US Patent
LigandPNGBDBM251677(US10100018, Example 13 | US9464060, 13)
Affinity DataIC50:  4nMT: 2°CAssay Description:Engagement of the LPA1 receptor by its ligand, oleoyl-L-α-lysophosphatidic acid (LPA), leads to the release of intracellular stores of calcium i...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetLysophosphatidic acid receptor 1(Homo sapiens (Human))
Takeda Pharmaceutical

US Patent
LigandPNGBDBM251725(US10100018, Example 61 | US9464060, 61)
Affinity DataIC50:  4nMT: 2°CAssay Description:Engagement of the LPA1 receptor by its ligand, oleoyl-L-α-lysophosphatidic acid (LPA), leads to the release of intracellular stores of calcium into ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetLysophosphatidic acid receptor 1(Homo sapiens (Human))
Takeda Pharmaceutical

US Patent
LigandPNGBDBM251725(US10100018, Example 61 | US9464060, 61)
Affinity DataIC50:  4nMT: 2°CAssay Description:Engagement of the LPA1 receptor by its ligand, oleoyl-L-α-lysophosphatidic acid (LPA), leads to the release of intracellular stores of calcium i...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetLysophosphatidic acid receptor 1(Homo sapiens (Human))
Takeda Pharmaceutical

US Patent
LigandPNGBDBM251729(US10100018, Example 65 | US9464060, 65)
Affinity DataIC50:  4nMT: 2°CAssay Description:Engagement of the LPA1 receptor by its ligand, oleoyl-L-α-lysophosphatidic acid (LPA), leads to the release of intracellular stores of calcium i...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetCholesterol 24-hydroxylase(Homo sapiens (Human))TBA
LigandPNGBDBM50609197(CHEMBL5282804)
Affinity DataIC50:  4.30nMAssay Description:Inhibition of full length N-terminal his6-tagged human CH24H (28 to 494 residues) expressed in Escherichia coli DH5alpha using [14C] cholesterol as s...More data for this Ligand-Target Pair
Ligand Info
In DepthDetails PubMed
TargetCholesterol 24-hydroxylase(Homo sapiens (Human))TBA
LigandPNGBDBM50609191(CHEMBL5271033)
Affinity DataIC50:  4.40nMAssay Description:Inhibition of full length N-terminal his6-tagged human CH24H (28 to 494 residues) expressed in Escherichia coli DH5alpha using [14C] cholesterol as s...More data for this Ligand-Target Pair
Ligand Info
In DepthDetails PubMed
TargetCholesterol 24-hydroxylase(Homo sapiens (Human))TBA
LigandPNGBDBM50609194(CHEMBL5269674)
Affinity DataIC50:  4.70nMAssay Description:Inhibition of full length N-terminal his6-tagged human CH24H (28 to 494 residues) expressed in Escherichia coli DH5alpha using [14C] cholesterol as s...More data for this Ligand-Target Pair
Ligand Info
In DepthDetails PubMed
TargetCholesterol 24-hydroxylase(Homo sapiens (Human))TBA
LigandPNGBDBM50609189(CHEMBL5289771)
Affinity DataIC50:  4.90nMAssay Description:Inhibition of full length N-terminal his6-tagged human CH24H (28 to 494 residues) expressed in Escherichia coli DH5alpha using [14C] cholesterol as s...More data for this Ligand-Target Pair
Ligand Info
In DepthDetails PubMed
TargetLysophosphatidic acid receptor 1(Homo sapiens (Human))
Takeda Pharmaceutical

US Patent
LigandPNGBDBM251726(US10100018, Example 62 | US9464060, 62)
Affinity DataIC50:  5nMT: 2°CAssay Description:Engagement of the LPA1 receptor by its ligand, oleoyl-L-α-lysophosphatidic acid (LPA), leads to the release of intracellular stores of calcium i...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetLysophosphatidic acid receptor 1(Homo sapiens (Human))
Takeda Pharmaceutical

US Patent
LigandPNGBDBM251729(US10100018, Example 65 | US9464060, 65)
Affinity DataIC50:  5nMT: 2°CAssay Description:Engagement of the LPA1 receptor by its ligand, oleoyl-L-α-lysophosphatidic acid (LPA), leads to the release of intracellular stores of calcium i...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetLysophosphatidic acid receptor 1(Homo sapiens (Human))
Takeda Pharmaceutical

US Patent
LigandPNGBDBM251695(US10100018, Example 31 | US9464060, 31)
Affinity DataIC50:  5nMT: 2°CAssay Description:Engagement of the LPA1 receptor by its ligand, oleoyl-L-α-lysophosphatidic acid (LPA), leads to the release of intracellular stores of calcium i...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetLysophosphatidic acid receptor 1(Homo sapiens (Human))
Takeda Pharmaceutical

US Patent
LigandPNGBDBM251730(US10100018, Example 66 | US9464060, 66)
Affinity DataIC50:  5nMT: 2°CAssay Description:Engagement of the LPA1 receptor by its ligand, oleoyl-L-α-lysophosphatidic acid (LPA), leads to the release of intracellular stores of calcium i...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetLysophosphatidic acid receptor 5(Homo sapiens (Human))
Takeda Pharmaceutical

US Patent
LigandPNGBDBM251695(US10100018, Example 31 | US9464060, 31)
Affinity DataIC50:  5nMT: 2°CAssay Description:Engagement of the LPA5 receptor by its ligand, oleoyl-L-α-lysophosphatidic acid (LPA), leads to the release of intracellular stores of calcium into ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetLysophosphatidic acid receptor 5(Homo sapiens (Human))
Takeda Pharmaceutical

US Patent
LigandPNGBDBM251730(US10100018, Example 66 | US9464060, 66)
Affinity DataIC50:  5nMT: 2°CAssay Description:Engagement of the LPA5 receptor by its ligand, oleoyl-L-α-lysophosphatidic acid (LPA), leads to the release of intracellular stores of calcium into ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetLysophosphatidic acid receptor 5(Homo sapiens (Human))
Takeda Pharmaceutical

US Patent
LigandPNGBDBM251731(US10100018, Example 67 | US9464060, 67)
Affinity DataIC50:  5nMT: 2°CAssay Description:Engagement of the LPA5 receptor by its ligand, oleoyl-L-α-lysophosphatidic acid (LPA), leads to the release of intracellular stores of calcium into ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
Displayed 1 to 50 (of 945 total ) | Next | Last >>
Jump to: